VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC(R) T-cell engager program, marking another step in preparing the company’s most advanced oncology candidate for future clinical development. The company announced that it has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase(R) technology. According to VERAXA, the collaboration is intended to support manufacturing, analytical development and nonclinical studies required before clinical testing. The partnership represents an important development milestone as the candidate advances toward IND/CTA-enabling studies.
VERAXA’s BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development. The cell line development partnership with ATUM is a critical step in ensuring that VERAXA can produce sufficient quantities of its therapeutic candidate for preclinical and eventual clinical trials. ATUM will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA’s lead therapeutic candidate, which is expected to streamline manufacturing processes and enhance product consistency.
The advancement of VERAXA’s lead BiTAC-TCE program underscores the company’s commitment to addressing unmet needs in oncology. By leveraging ATUM’s expertise, VERAXA aims to accelerate the timeline from preclinical development to clinical trials. The company’s focus on reducing toxicity through more selective T-cell engagers could position it as a differentiated player in the immuno-oncology space. Investors can find the latest news and updates relating to VRXA in the company’s newsroom at https://ibn.fm/VRXA. This development highlights the progress VERAXA is making in advancing its pipeline toward clinical evaluation.
